UBIGENE

Ubigene

banner

CRISPR Library Virus & Cell Pool

Chat with an Expert

CRISPR Library Virus & Cell Pool

CRISPR library cell pools are generated by infecting target cells with a CRISPR library viral containing diverse sgRNAs at a low infect MOI. This approach creates a cell pool, each carrying different sgRNAs and exhibiting distinct gene knockout backgrounds.By applying specific selection pressures—such as drug treatment, serial passaging, or flow cytometry sorting—cell subpopulations with particular phenotypes can be enriched or depleted. Subsequent next-generation sequencing (NGS) enables the systematic identification of key genes associated with these phenotypes.This technology is widely used for: Investigating mechanisms of drug resistance,studying tumor metastasis and invasion,Elucidating immune interactions and regulatory mechanisms,or genome-wide or customized target screening.

Why choose Ubigene?

Extensive In-Stock Resources

· 400+ Screening-ready Cell Pools covering a wide range of tumor and commonly used cell lines. · Short turnaround time — delivery in as fast as 1 week, saving valuable time on early-stage library construction.

High-Titer and Uniform Virus

· High viral titer exceeding 1*10⁸ TU/mL, ensuring efficient cell infection and stable library construction · Even sgRNA distribution, guaranteeing experimental reproducibility and reliable screening outcomes.

High Cell Coverage, Low infect MOI

Low infect MOI with ample wild-type cells ensures most cells carry a single sgRNA, maintaining high library quality and coverage across multiple passages.

Robust Quality Assurance

Ubigene's CRISPR library cell pools undergo rigorous quality control, including mycoplasma and bacterial testing. NGS verification ensures high sgRNA coverage (≥99%), and stable distribution is maintained throughout cell passaging, guaranteeing reliable screening results.

Flexible Service Options

Ubigene provides off-the-shelf and custom services, enabling fast project startup and supporting comprehensive, tailored research workflows.

Workflow

gRNA Library Design & Plasmid Construction

Lentiviral Packaging & Titer Assessment

MOI Optimization & Cell Pool Infection

Antibiotic Selection & Cell Pool Generation

NGS Sequencing & Data Analysis

CRISPR Library Virus & Cell Pool Services Overview

CRISPR Library Virus Service

In-Stock CRISPR Library Virus

After plasmid library amplification, lentiviral packaging, virus concentration, and titer assessment are performed to ensure a viral titer > 1 * 10⁸ TU/mL.

Turnaround

1 week

Deliverables

Corresponding CRISPR library virus and COA report.

Custom CRISPR Library Virus

sgRNAs are designed de novo, and a custom plasmid library is constructed. Following plasmid amplification and NGS validation, lentiviral packaging, concentration, and titer assessment are performed to ensure a viral titer > 1 * 10⁸ TU/mL.

Turnaround

6-9 weeks

Deliverables

Corresponding CRISPR library virus, COA report, and NGS sequencing report of the custom CRISPR library plasmid.

CRISPR Library Cell Pool Service

In-Stock Screening-ready Cell Pool

Screening-ready Cell Pools. Cells undergo thaw recovery, bacterial and mycoplasma testing, and NGS validation to ensure quality before delivery.

Turnaround

1 week

Deliverables

CRISPR Library Cell Pool with ≥300* or 500* coverage, NGS sequencing report

CRISPR Library Cell Pool in Development

Using in-stock CRISPR library viruses, target cells are subjected to MOI optimization, viral infection, drug selection, and NGS sequencing to generate CRISPR library cell pools.

Turnaround

6-9 weeks

Deliverables

CRISPR Library Cell Pool with ≥300* or 500* coverage, NGS sequencing report

Custom CRISPR Library Cell Pool

Design sgRNAs, construct a custom plasmid library, and package it into lentivirus. Next, perform MOI optimization, viral infection, drug selection, and NGS-based quality control to generate a fully

Turnaround

11-13 weeks

Deliverables

CRISPR Library Cell Pool with ≥300* or 500* coverage, NGS sequencing report

*For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.

Case Studies

1. CRISPR Library Virus Packaging & Titer Assessment

View Picture

Certificate of Analysis

View Picture

Melt Curve Plot

2. MOI Optimization for cell Infection

View Picture

Set up multiple infection gradients with different MOIs to test viral infection efficiency. Calculate the corresponding cell infection rates and select the MOI that achieves approximately 30% infection efficiency as the condition for library virus infection.

View Picture

Proportion of Cells Receiving Multiple sgRNAs at Different Infection Efficiencies

View Picture

Impact of Cell Coverage on sgRNA Retention During Passaging

3. Cell Images

View Picture

5637 Cell

View Picture

A549 Cell

View Picture

UM-UC-3 Cell

4. NGS Sequencing of CRISPR Library Cell Pool for sgRNA Coverage

1.Next-generation sequencing (NGS) results for custom CRISPR library cell pool.

View Picture

View Picture

View Picture

2.Next-generation sequencing (NGS) results of whole-genome knockout library cell pool.

View Picture

View Picture

View Picture

FAQs

1. Why is the MOI for 30% virus infection efficiency chosen as the viral infection condition for library cell construction experiments?

    An MOI of 0.3 is optimal for CRISPR screening:
  • Single-Gene Editing: Ensures each cell is infected by only one viral particle, minimizing multiple sgRNA expression.
  • Efficiency and Viability: Achieves 30% infection without significant toxicity, maintaining cell health.
  • Coverage: Ensures sufficient sgRNA expression for robust screening results.
  • Practicality: Reduces viral particle use, lowers cost, and simplifies procedures.

Contact Us

Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours

* Name

* Email

* Institution

* Products & Services of Interest

If email is not available, how else can we reach you?

How did you hear about us?

Logo
E-mail: info@ubigene.com
WhatsAPP: +86 153 6067 3248
TEL: +86 153 6067 3248(Int'l)
Copyright © 2025 Ubigene. All rights reserved.